Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs MasTec Inc — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.57 (market cap $94.46M), while MasTec Inc trades at $213.87 (market cap $17.40B). The key difference: MasTec Inc is far larger — about 184.2× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and T-Rex 2X Inverse MSTR Daily Target ETF is more actively traded (104,717,733 versus 1,415,821). Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and MasTec Inc for 23 Days on average.
| MSTZ | MTZ | |
|---|---|---|
Market Cap | $94.46M | $17.40B |
Volume | 104,717,733 | 1,415,821 |
Sector | Leveraged / Inverse | Industrials |
52-Week High | $27.92 | $437.51 |
52-Week Low | $2.29 | $190.08 |
Typical Hold Time | 8 Days | 23 Days |
Enterprise Value | — | $20.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ is trading at $2.54, down 4.51% today, with technical indicators showing a bearish trend as moving averages signal selling pressure. The stock lacks key financial ratio data, making fundamental assessment challenging. Recent ETF coverage highlights its inclusion in leveraged/inverse ETF discussions, though specific company performance details are limited.
The outlook remains cautious due to incomplete financial disclosures and bearish technical signals. Investment opportunities depend on forthcoming earnings clarity, while risks include volatility from limited institutional coverage and market sentiment shifts. Investors should await detailed financial updates for informed decisions.
MasTec (MTZ) trades at $216.11, down 3.25% on the day, with technical indicators showing a bearish trend as the stock trades below key moving averages. The company maintains strong fundamentals with revenue growth from $14.3B in 2025 to $16.1B projected for 2026, and net income improving to $494M. Recent news highlights MTZ's positioning in infrastructure investment cycles, particularly in power delivery and data center markets, supported by a record $21.4B backlog.
The outlook remains positive given analyst consensus of 32 Buy ratings and a $408.58 price target, representing 89% upside potential. Key risks include premium valuation metrics (P/E 34.5), weak cash flow trends, and communications segment softness. The stock's current discount to analyst targets presents a compelling opportunity if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
